Cognetivity Neurosciences Ltd. (CGNSF)
Cognetivity Neurosciences Ltd. operates in the Medical - Healthcare Information Services industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $8,959. On trailing twelve-month figures it carries a trailing P/E of -0.13, a net margin of -16386.7%. Its beta of 0.74 implies it has historically moved less than the broad market.
Cognetivity Neurosciences Ltd. is a healthcare firm focused on advanced cognitive assessment. The company has developed a sophisticated platform for cognitive testing, designed for use across diverse settings including medical facilities, commercial environments, and by individual consumers. This innovative system's primary goal is to identify the very first signs of cognitive impairment through a comprehensive evaluation of broad brain functions, thereby assisting in the diagnosis of conditions like dementia. In addition to its core platform, Cognetivity also provides OptiMind, a dedicated wellness application. Established in 2015, the company initially operated under the name Utor Capital Corp. before officially rebranding to Cognetivity Neurosciences Ltd. in December 2017. Its main offices are situated in Vancouver, Canada.
Cognetivity Neurosciences Ltd. is most often compared with the following Healthcare names: